DE3783958T2 - Verzoegerte abgabe von makromolekularen polypeptiden. - Google Patents

Verzoegerte abgabe von makromolekularen polypeptiden.

Info

Publication number
DE3783958T2
DE3783958T2 DE8787304570T DE3783958T DE3783958T2 DE 3783958 T2 DE3783958 T2 DE 3783958T2 DE 8787304570 T DE8787304570 T DE 8787304570T DE 3783958 T DE3783958 T DE 3783958T DE 3783958 T2 DE3783958 T2 DE 3783958T2
Authority
DE
Germany
Prior art keywords
delayed delivery
macromolecular polypeptides
macromolecular
polypeptides
micro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787304570T
Other languages
English (en)
Other versions
DE3783958T3 (de
DE3783958D1 (de
Inventor
Deborah Ann Eppstein
Brian Bloor Schryver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25348017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3783958(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Application granted granted Critical
Publication of DE3783958D1 publication Critical patent/DE3783958D1/de
Publication of DE3783958T2 publication Critical patent/DE3783958T2/de
Publication of DE3783958T3 publication Critical patent/DE3783958T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
DE3783958T 1986-05-23 1987-05-22 Verzögerte Abgabe von makromolekularen Polypeptiden. Expired - Fee Related DE3783958T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/866,625 US4962091A (en) 1986-05-23 1986-05-23 Controlled release of macromolecular polypeptides

Publications (3)

Publication Number Publication Date
DE3783958D1 DE3783958D1 (de) 1993-03-18
DE3783958T2 true DE3783958T2 (de) 1993-06-09
DE3783958T3 DE3783958T3 (de) 2003-08-07

Family

ID=25348017

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3783958T Expired - Fee Related DE3783958T3 (de) 1986-05-23 1987-05-22 Verzögerte Abgabe von makromolekularen Polypeptiden.

Country Status (10)

Country Link
US (1) US4962091A (de)
EP (1) EP0251476B2 (de)
JP (1) JP2594560B2 (de)
AT (1) ATE85214T1 (de)
AU (1) AU608225B2 (de)
CA (1) CA1293443C (de)
DE (1) DE3783958T3 (de)
ES (1) ES2039437T5 (de)
HK (1) HK38997A (de)
NZ (1) NZ220403A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932603A1 (de) * 1999-07-13 2001-01-25 Gruenenthal Gmbh Wirkstoffhaltiger Mehrschichtfilm aus in situ vernetzten hydrophilen Polymeren

Families Citing this family (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5904717A (en) * 1986-01-28 1999-05-18 Thm Biomedical, Inc. Method and device for reconstruction of articular cartilage
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US5502158A (en) * 1988-08-08 1996-03-26 Ecopol, Llc Degradable polymer composition
US5444113A (en) * 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US5633002A (en) * 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
US5288487A (en) * 1989-02-28 1994-02-22 Morinaga Milk Industry Co., Ltd. Human monocyte-macrophage-CSF preparations
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
CH681425A5 (de) * 1990-11-14 1993-03-31 Debio Rech Pharma Sa
CH679207A5 (de) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
US5252342A (en) * 1990-03-05 1993-10-12 The Regents Of The University Of California Enhancement of anti-neoplastic drug efficacy using EGF
US5597798A (en) * 1990-03-05 1997-01-28 The Regents Of The University Of California Taxol and epidermal growth factor used to enhance treatment of ovarian cancer
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
US6517859B1 (en) * 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
DE69133136T2 (de) * 1990-05-16 2003-06-18 Southern Res Inst Birmingham Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
IL99497A (en) * 1990-10-01 1997-03-18 Res Dev Foundation Synergistic compositions comprising tnf and il-4
WO1992006112A1 (en) * 1990-10-09 1992-04-16 Sri International Activated ctap and analogs thereof and their use
NZ240214A (en) * 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
ES2083152T3 (es) * 1990-11-30 1996-04-01 Monoclonetics Int Metodos para el diagnostico de dolores cronicos lumbares y cervicales.
MY108267A (en) * 1991-01-16 1996-09-30 Schering Corp Use of interleukin-10 in adoptive immunotherapy of cancer
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
AU8303691A (en) * 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5356629A (en) * 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
CA2129514A1 (en) * 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
ZA932273B (en) * 1992-03-30 1993-11-26 Alza Corp Additives for bioerodible polymers to regulate degradation
US5540912A (en) * 1992-03-30 1996-07-30 Alza Corporation Viscous suspensions of controlled-release drug particles
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US7105158B1 (en) * 1992-11-16 2006-09-12 The Corporation Of Mercer University Methods of administering microencapsulated materials for immune modulated diseases
CA2150803C (en) * 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ES2153418T3 (es) * 1993-02-23 2001-03-01 Genentech Inc Estabilizacion de polipeptidos tratados con solventes organicos por medio de excipientes.
NZ265555A (en) * 1993-04-19 1997-09-22 Medisorb Technologies Internat Biodegradable microparticle compositions of antisense oligodeoxyribonucleotides
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5635216A (en) * 1993-12-16 1997-06-03 Eli Lilly And Company Microparticle compositions containing peptides, and methods for the preparation thereof
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
EP0670733A1 (de) * 1993-09-29 1995-09-13 Alcon Laboratories, Inc. Zusammensetzungen welche wachstumsfaktoren und antineoplastische mitteln enthalten
JPH07100178A (ja) * 1993-10-01 1995-04-18 Sadako Ueda 天然炭酸カルシウム入浴剤
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US6913767B1 (en) * 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
WO1995011707A1 (en) * 1993-10-28 1995-05-04 Thm Biomedical, Inc. Improved process and device for treating and healing a bone void
EP0741580A4 (de) * 1993-12-14 2001-07-11 Univ Johns Hopkins Med Die kontrollierte freisetzung von pharmazeutisch aktiven substanzen in der immuntherapie
ATE199316T1 (de) * 1993-12-23 2001-03-15 Bruno Gander Mit antigen beladene mikropartikel und pharmazeutische zubereitungen, die diese mikropartikel enthalten.
DE69524398T2 (de) * 1994-04-08 2002-07-18 Atrix Lab Inc Flüssige mittel zur wirkstoffabgabe
US5981825A (en) 1994-05-13 1999-11-09 Thm Biomedical, Inc. Device and methods for in vivo culturing of diverse tissue cells
US5681568A (en) * 1994-08-19 1997-10-28 Cambridge Neuroscience, Inc. Device for delivery of substances and methods of use thereof
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
JPH08215516A (ja) * 1995-02-10 1996-08-27 Hiroshi Kaneko 浴槽水の浄化・活性化フィルタ−
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
ATE377418T1 (de) 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
US5916597A (en) * 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
EP0765660A3 (de) * 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Mikrokapseln enthaltend 2-Piperazinon-1-essigsäure Verbindungen
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6902584B2 (en) 1995-10-16 2005-06-07 Depuy Spine, Inc. Bone grafting matrix
US5776193A (en) 1995-10-16 1998-07-07 Orquest, Inc. Bone grafting matrix
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
ATE227980T1 (de) 1996-03-28 2002-12-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung und deren herstellung
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
DK0949905T3 (da) 1996-12-20 2001-10-22 Alza Corp Injicertbart depotelpræparat og fremgangsmåde til fremstilling
AU3179999A (en) 1997-12-16 1999-07-05 Regents Of The University Of Minnesota Methods to treat undesirable immune responses
DK1061948T3 (da) 1998-03-20 2003-03-31 Takeda Chemical Industries Ltd Præparat til vedvarende frigivelse af et fysiologisk aktivt polypeptid samt fremstilling deraf
US7128927B1 (en) 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
CA2342912A1 (en) * 1998-09-02 2000-03-09 Point Biomedical Corporation Local delivery of medications to the heart
ATE228021T1 (de) * 1998-09-11 2002-12-15 Gerhard Dr Schmidmaier Biologisch aktive implantate
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
CN1339964A (zh) * 1999-02-19 2002-03-13 生化研究股份公司 用以生产微胶囊的生物可降解复合材料
EP1161257A2 (de) 1999-03-17 2001-12-12 Novartis AG Tgf-beta enthaltende pharmazeutische zusammensetzungen
EP1173151B1 (de) 1999-04-16 2003-07-09 Novo Nordisk A/S Trockene formbare arzneistoffformulierung
US6398774B1 (en) 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US7678087B2 (en) * 1999-09-29 2010-03-16 Heska Corporation Equine intranasal delivery system
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
NZ520201A (en) * 2000-02-08 2004-04-30 Allergan Inc Botulinum toxin pharmaceutical compositions comprising a polysaccharide
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
CA2400319C (en) 2000-03-15 2008-09-16 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US6927223B1 (en) 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
DE60127139T2 (de) * 2000-07-14 2007-12-13 Novo Nordisk A/S Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial
DE60128261T3 (de) 2000-12-21 2016-06-30 Alrise Biosystems Gmbh Verfahren umfassend einen induzierten phasenübergang zur herstellung von hydrophobe wirkstoffe enthaltenden mikropartikeln
US20020164372A1 (en) * 2000-12-29 2002-11-07 Sidney Pestka Controlled release systems for polymers
MXPA03010679A (es) * 2001-05-23 2004-03-02 Tanabe Seiyaku Co Una composicion para acelerar la cicatrizacion de fractura osea.
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
JP2004535431A (ja) 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
DE10146251A1 (de) * 2001-09-20 2003-04-17 Gruenenthal Gmbh Vorrichtung zur Herstellung eines pharmazeutischen Films
WO2003043574A2 (en) * 2001-11-19 2003-05-30 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
EP1575481A4 (de) 2002-03-01 2010-01-06 Celltech R & D Inc Verfahren zur erhöhung oder verringerung der knochendichte
EP1509182A4 (de) * 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc Implantierbare polymere vorrichtung zur verzögerten freisetzung von buprenorphin
WO2004004702A2 (en) 2002-07-09 2004-01-15 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20080274989A1 (en) * 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050106731A1 (en) * 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20080176812A1 (en) * 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
WO2004045531A2 (en) * 2002-11-14 2004-06-03 Cornell Research Foundation, Inc. Protection of cardiac myocardium
WO2004048552A2 (en) 2002-11-21 2004-06-10 Celltech R & D, Inc. Modulating immune responses
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US7094785B1 (en) 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
US20070026069A1 (en) * 2003-03-28 2007-02-01 Shastri Venkatram P Biommetic hierarchies using functionalized nanoparticles as building blocks
AU2004228017C1 (en) * 2003-03-31 2010-06-03 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
KR101105486B1 (ko) * 2003-04-02 2012-01-13 아레스 트레이딩 에스.에이. Ｆｓｈ 및 ｌｈ과 비이온성 계면활성제의 액상 약제학적 제제
WO2004098634A2 (en) * 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)
DK1638595T3 (da) * 2003-06-20 2013-04-08 Ares Trading Sa Frysetørrede FSH-/LH-formuleringer
US20050053612A1 (en) * 2003-08-20 2005-03-10 Granstein Richard D. Nucleotide regulation of immune responses
US20050085557A1 (en) * 2003-09-05 2005-04-21 Paul Wentworth Therapeutic procedures
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
US7164008B2 (en) * 2003-11-17 2007-01-16 University Of Iowa Research Foundation Isolated complexes of endotoxin and MD-2
EP1723422A2 (de) * 2004-03-05 2006-11-22 The Scripps Research Institute Glycan-mikroarray mit hohem durchsatz
US8613934B2 (en) * 2004-03-22 2013-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cellular and viral inactivation
WO2005107817A2 (en) 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
US20060194726A1 (en) * 2004-05-25 2006-08-31 Rueger David C Methods of treating cartilage defects
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
AU2005330703A1 (en) * 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
NZ584340A (en) 2004-08-18 2010-09-30 Novabiotics Ltd Antimicrobial peptides comprising an arginine- and/or lysine-containing motif
WO2006068758A2 (en) * 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention and treatment of breast cancer
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006076504A2 (en) * 2005-01-13 2006-07-20 University Of Iowa Research Foundation Sialic acid permease system
US20060194740A1 (en) * 2005-02-25 2006-08-31 Ulevitch Richard J NOD1 as an anti-tumor agent
CN101501055B (zh) * 2005-06-23 2016-05-11 贝勒医学院 负性免疫调节因子的调节和免疫疗法应用
PL1976863T3 (pl) 2005-12-22 2013-07-31 Novabiotics Ltd Cykliczne peptydy przeciwbakteryjne
US20090069241A1 (en) * 2006-02-15 2009-03-12 Yale University Compositions and Methods for Use of Pigment Epithelial Derived Factor (PEDF) Peptide Fragments
US8088396B2 (en) * 2006-03-01 2012-01-03 University Of Iowa Research Foundation Isolated complexes of endotoxin and modified MD-2
US20070265170A1 (en) * 2006-05-15 2007-11-15 Ola Blixt Detection, prevention and treatment of ovarian cancer
WO2008036838A2 (en) * 2006-09-20 2008-03-27 University Of Iowa Research Foundation Isolated complexes of covalently cross-linked endotoxin and modified md-2
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
CN101678082B (zh) 2007-03-26 2013-06-19 再生医药有限公司 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
DK2164967T3 (en) 2007-05-31 2015-10-19 Univ Iowa Res Found Reduction of off-target rna interferenstoksicitet
EP2155207A2 (de) 2007-05-31 2010-02-24 Government Of The United States Of America As Represented by Secretary of the Dep. of Health and Human Services National Institute of Health N-acetyl-mannosamin als therapeutikum
JP2011505144A (ja) * 2007-11-30 2011-02-24 ベイラー カレッジ オブ メディシン 樹状細胞ワクチン組成物およびその使用
TWI352717B (en) 2007-12-11 2011-11-21 Ind Tech Res Inst A tenacity adjuster, a biodegradable material comp
US20110112079A1 (en) * 2008-01-09 2011-05-12 Thomas Craig J Phosphodiesterase inhibitors
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
AR067447A1 (es) * 2008-07-03 2009-10-14 Monte Verde S A Un procedimiento para preparar una composicion farmaceutica que contiene los proincipios activos glucosamina y meloxicam y el uso de dicha asociacion para el tratamiento de patologias degenerativas osteo-articulares
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8545855B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8545806B2 (en) * 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9056047B2 (en) 2008-10-31 2015-06-16 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8788211B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8256233B2 (en) * 2008-10-31 2012-09-04 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8551505B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8784385B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Frozen piercing implements and methods for piercing a substrate
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US8545857B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8551506B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100178038A1 (en) * 2009-01-12 2010-07-15 Mediatek Inc. Video player
US9808504B2 (en) 2009-09-22 2017-11-07 Yale University Immunogenic epitopes as targets for universal cancer vaccines
GB201016733D0 (en) 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
US8632839B2 (en) * 2010-10-19 2014-01-21 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
EP2468269A1 (de) 2010-11-26 2012-06-27 Universitätsklinikum Münster Nitridoxidspender bei der Behandlung von Nitridoxidmangel-induzierten Störungen der Hirnmikrozirkulation
WO2012076842A1 (en) 2010-12-09 2012-06-14 University Of Durham Synthetic retinoids for control of cell differentiation
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
CA2827380C (en) 2011-02-12 2020-08-25 University Of Iowa Research Foundation Therapeutic nucleic acids
US9446112B2 (en) 2011-07-12 2016-09-20 Philadelphia Health & Education Corporation Clostridium difficile DNA vaccine
WO2013013178A1 (en) 2011-07-21 2013-01-24 Kansas State University Research Foundation Sesquiterpenes for antifungal applications
WO2014011663A1 (en) 2012-07-09 2014-01-16 Board Of Trustees Of Michigan State University Inhibitors of bacterial diguanylate cyclase
CA2889020A1 (en) 2012-10-23 2014-05-01 Cornell University Treatment of metastatic breast cancer
CA2890258C (en) * 2012-11-02 2020-10-20 Cytuvax Composition comprising cytokine macro-aggregates
EP2951199A4 (de) 2013-01-31 2016-07-20 Univ Jefferson Fusionsproteine zur modulation von regulatorischen und effektor-t-zellen
US8957044B2 (en) 2013-03-01 2015-02-17 Wake Forest University Health Sciences Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
WO2015021415A1 (en) 2013-08-09 2015-02-12 The Scripps Research Institute Transcriptome-wide design of selective, bioactive small molecules targeting rna
US10500232B2 (en) 2013-08-26 2019-12-10 The J. David Gladstone Ins., a testamentary trust established under the Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
EP3043822A1 (de) 2013-09-11 2016-07-20 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Zusammensetzungen zur herstellung von kardiomyozyten
EP3146051B8 (de) 2014-05-20 2019-11-27 University of Iowa Research Foundation Therapeutische verbindungen für huntington-krankheit
US10519443B2 (en) 2014-09-08 2019-12-31 University Of Iowa Research Foundation Microrna inhibitor system and methods of use thereof
US9758781B2 (en) 2014-09-30 2017-09-12 University Of Iowa Research Foundation Methods to prevent and treat autosomal dominant non-syndromic hearing loss
CA2979640A1 (en) 2015-02-25 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sialylation-increasing therapies for diseases associated with oxidative stress
WO2016196507A1 (en) 2015-05-29 2016-12-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
WO2016199146A1 (en) * 2015-06-09 2016-12-15 B. G. Negev Technologies And Applications Ltd A controlled release system for pulmonary delivery of surfactant protein d
EP3331988B1 (de) 2015-08-07 2023-09-20 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Chemische reprogrammierung zur erzeugung neuronaler zellen
US10822584B2 (en) * 2015-12-17 2020-11-03 Life Technologies Corporation Pellets used in cell culture and methods of making thereof
US10273476B2 (en) 2016-04-30 2019-04-30 University Of Iowa Research Foundation MicroRNA-200 based approaches for modulating bone formation inhibition and bone regeneration
EP3481374A1 (de) 2016-07-08 2019-05-15 The Scripps Research Institute Desensibilisierung von mastzellen durch co-präsentation von antigenen mit hochaffinen mastzellen-siglec-liganden
WO2018224813A1 (en) 2017-06-06 2018-12-13 Novabiotics Limited Use of cysteamine compositions
WO2019010135A1 (en) 2017-07-05 2019-01-10 Arizona Board Of Regents On Behalf Of Arizona State University VACCINE AGAINST NECROTIC ENERTITIES IN POULTRY
US11821042B2 (en) 2017-07-10 2023-11-21 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment
WO2019018666A1 (en) 2017-07-21 2019-01-24 University Of North Dakota INHIBITION OF FAK-AKT INTERACTION TO INHIBIT METASTASES
CA3111076A1 (en) 2018-08-30 2020-03-05 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ascl1
AU2019360638A1 (en) 2018-10-17 2021-06-03 Novabiotics Limited Dosage regime
WO2020140007A1 (en) 2018-12-28 2020-07-02 University Of Rochester Gene therapy for best1 dominant mutations
WO2021007515A1 (en) 2019-07-11 2021-01-14 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with micrornas and other factors
WO2021086958A1 (en) 2019-10-28 2021-05-06 The Scripps Research Institute Immune cell receptor antibodies conjugated to high affinity siglec-ligands
US20230053688A1 (en) 2020-01-10 2023-02-23 Cornell University Methods to alter latency in ebv+ malignancies
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
WO2022159496A2 (en) 2021-01-19 2022-07-28 The J. David Gladstone Institutes, A Testamentary Trust Under The Will Of J. David Gladstone Gene activation targets for enhanced human t cell function
WO2023250249A1 (en) 2022-06-23 2023-12-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Hmgb1 inhibitors for treatment of apoe4-related tauopathies including alzheimer's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419340A (en) * 1969-03-24 1983-12-06 University Of Delaware Controlled release of anticancer agents from biodegradable polymers
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4512972A (en) * 1980-06-30 1985-04-23 Kureha Chemical Industry Co., Ltd. Nasal preparation and processes for their production
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
CA1196864A (en) * 1983-06-10 1985-11-19 Mattheus F.A. Goosen Controlled release of injectable and implantable insulin compositions
US4637931A (en) * 1984-10-09 1987-01-20 The United States Of America As Represented By The Secretary Of The Army Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material
US4678809A (en) * 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932603A1 (de) * 1999-07-13 2001-01-25 Gruenenthal Gmbh Wirkstoffhaltiger Mehrschichtfilm aus in situ vernetzten hydrophilen Polymeren

Also Published As

Publication number Publication date
HK38997A (en) 1997-04-04
US4962091A (en) 1990-10-09
CA1293443C (en) 1991-12-24
EP0251476B2 (de) 2002-11-27
ES2039437T5 (es) 2003-06-16
DE3783958T3 (de) 2003-08-07
EP0251476A1 (de) 1988-01-07
JPS632930A (ja) 1988-01-07
NZ220403A (en) 1990-06-26
JP2594560B2 (ja) 1997-03-26
EP0251476B1 (de) 1993-02-03
DE3783958D1 (de) 1993-03-18
AU7333287A (en) 1987-11-26
ES2039437T3 (es) 1993-10-01
AU608225B2 (en) 1991-03-28
ATE85214T1 (de) 1993-02-15

Similar Documents

Publication Publication Date Title
DE3783958T3 (de) Verzögerte Abgabe von makromolekularen Polypeptiden.
DE3750619D1 (de) System zur Abgabe von Arzneistoffen.
DE58904179D1 (de) Septum fuer implantierbare vorrichtungen zur abgabe von wirkstoffen.
IT8521922A0 (it) Sistema di somministrazione di farmaci.
DK288987D0 (da) Et afgivelsessystem til doseringsformerne forhalet afgivelse, samt dettes fremstilling
DE68910833D1 (de) Polylactid-zubereitungen.
DE68908456T2 (de) Matrix zur Wirkstoffabgabe.
DE68901986D1 (de) Turbomolekularpumpe und deren betriebsverfahren.
DE68910867D1 (de) Matrix für die transdermale Abgabe von Arzneimitteln.
DE3769379D1 (de) Entzuendungshemmende wirkstoffe, pharmazeutische zusammensetzungen und verfahren zur bekaempfung von entzuendungen.
ATE64529T1 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
NO882897L (no) Avleveringssystem for legemidler.
DK304485A (da) Faste laegemiddelpraeparater med dihydropyridiner samt fremstilling deraf
DE3880227T2 (de) Vorbeugung der nachoxidaton von methacrolein.
DK642588A (da) Indanderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
DE3869670D1 (de) Latex fuer die immobilisierung von physiologisch aktiven verbindungen und reaktiver latex, der diesen latex verwendet.
NO903844L (no) Medikamentavgivelsesblandinger basert paa biologiske celler eller komponenter derav og fremgangsmaater.
DE69002034T2 (de) Vorrichtung mit gesteuerter Wirkstoffabgabe.
DE3867086D1 (de) Benzothiepino(5,4-c)pyridazin-verbindungen und ihre pharmazeutischen wirkungen.
FI890729A0 (fi) Anordning foer montering av delarna i en vinkelremledning.
DE3869268D1 (de) Vorrichtng mit verzoegerter abgabe von arzneimitteln mit donnanartiger modulation von geladenen unloeslichen harzen.
DE3788338T2 (de) Vorbehandlungswirkstoff zur perkutanen verabreichung.
ES2019634B3 (es) Terapia con clorfeniramina.
IT8921567A0 (it) Derivati peptidici farmacologicamente attivi e preparazioni farmaceutiche che li contengono.
IT8420407A0 (it) Composizione anti-acne a base di tiossolone e di almeno un altro principio attivo.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Free format text: BARZ, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 80803 MUENCHEN

8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: SYNTEX (U.S.A.) LLC, PALO ALTO, CALIF., US

8339 Ceased/non-payment of the annual fee